An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

von Tresckow Bastian; Morschhauser Franck; Ribrag Vincent; Topp Max S.; Chien Caly; Seetharam Shobha; Aquino Regina; Kotoulek Sonja; de Boer Carla J.; Engert Andreas

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

【24h】

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

机译：CSF-1R抑制剂JNJ-40346527在复发或难治性霍奇金淋巴瘤患者中的开放标签，多中心I / II期研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This phase I/II study investigated JNJ-40346527, a selective inhibitor of the colony-stimulating factor-1 receptor (CSF-1R) tyrosine kinase as treatment for relapsed or refractory classical Hodgkin lymphoma (cHL).

机译：目的：该I / II期研究对JNJ-40346527（一种集落刺激因子1受体（CSF-1R）酪氨酸激酶的选择性抑制剂）进行了研究，以治疗复发性或难治性经典霍奇金淋巴瘤（cHL）。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2015年第8期|共8页
作者
von Tresckow Bastian; Morschhauser Franck; Ribrag Vincent; Topp Max S.; Chien Caly; Seetharam Shobha; Aquino Regina; Kotoulek Sonja; de Boer Carla J.; Engert Andreas;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma [J] . von Tresckow Bastian, Morschhauser Franck, Ribrag Vincent, Clinical cancer research: an official journal of the American Association for Cancer Research . 2015,第8期

机译：CSF-1R抑制剂JNJ-40346527在复发或难治性霍奇金淋巴瘤患者中的开放标签，多中心I / II期研究
2. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. [J] . Julie M Vose, Jonathan W Friedberg, Edmund K Waller, Leukemia and lymphoma . 2013,第4期

机译：难治性或复发性非霍奇金淋巴瘤患者的Plk1抑制剂BI 2536：I期，开放标签，单剂量递增研究。
3. The Plk1 inhibitor BI 2536 in patients with refractory or relapsed non-Hodgkin lymphoma: a phase I, open-label, single dose-escalation study. [J] . Julie M Vose, Jonathan W Friedberg, Edmund K Waller, Leukemia and lymphoma . 2013,第4期

机译：PLK1抑制剂BI 2536在难治性或复发的非霍奇金淋巴瘤患者中：I相，开放标签，单剂量升级研究。
4. Efficiency and Toxmcity of the Fludarabine and Cyclo- Phosphamide Combined Therapy in Relapsed/ Resistant Patients with B-cell Chronic Lymphocytic Leukaemia (CLL)-Polish Multicenter Study [C] . M. Kowal, A. Dmoszynska, D. Jawniak, European Haematology Association . 2002

机译：B-Cell慢性淋巴细胞白血病（CLL） - 渗透多中心研究的复发/抗性患者复发/抗性患者的氟氮胺碱和环磷酰胺联合治疗的效率和毒性
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase II Single-Arm Open-Label Multicenter Study to Evaluate the Efficacy and Safety of P276-00 a Cyclin Dependent Kinase Inhibitor in Patients with Relapsed or Refractory Mantle Cell Lymphoma [O] . Ryan D. Cassaday, Andre Goy, Suresh Advani, -1

机译：II期单臂开放标签多中心研究用于评估P276-00（一种细胞周期蛋白依赖性激酶抑制剂）在复发性或难治性套细胞淋巴瘤患者中的疗效和安全性
7. An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma [O] . Bastian von Tresckow, Franck Morschhauser, Vincent Ribrag, 2015

机译：复发或难治性霍奇金淋巴瘤患者的患者JNJ-40346527，CSF-1R抑制剂的开放标签，多中心，相I / II研究

An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅